Adrian Pay, MD
Internal Medicine · Amarillo, TXNPI 1417041203
Payments from drug & device makers
Across 412 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Novo Nordisk$818
- AstraZeneca$748
- Pfizer$672
- GSK$570
- Lilly USA, LLC$468
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,51799%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 72 | $1,569 |
| Novo Nordisk | 31 | $818 |
| AstraZeneca(2 entities) | 40 | $748 |
| Pfizer | 49 | $672 |
| GSK | 28 | $570 |
| Lilly USA, LLC | 22 | $468 |
| AbbVie(2 entities) | 16 | $374 |
| Eisai Inc. | 12 | $346 |
| Johnson & Johnson | 8 | $320 |
| E.r. Squibb & Sons, L.L.C. | 15 | $263 |
| Phathom Pharmaceuticals, Inc. | 6 | $227 |
| Astellas Pharma US Inc | 7 | $197 |
| Mylan Specialty L.p. | 12 | $188 |
| Lundbeck LLC | 11 | $181 |
| Viiv Healthcare Company | 4 | $178 |
| Novartis | 6 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $159 |
| Merck | 10 | $155 |
| Ferring Pharmaceuticals Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Exact Sciences | 6 | $111 |
| Melinta Therapeutics, LLC | 5 | $97 |
| Bayer | 5 | $85 |
| Avanir Pharmaceuticals, Inc. | 4 | $60 |
| Theratechnologies Inc. | 3 | $58 |
| Amgen | 4 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Biogen | 2 | $34 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Amneal Pharmaceuticals LLC | 2 | $23 |
| SK Life Science, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,602 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $150,954 |
| OzempicSemaglutide | 129 | $141,701 |
| EliquisApixaban | 57 | $40,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $39,800 |
| JanuviaSitagliptin Phosphate | 40 | $33,045 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $15,851 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $15,623 |
| MounjaroTirzepatide | 14 | $15,289 |
| TradjentaLinagliptin | 28 | $14,966 |
| FarxigaDapagliflozin Propanediol | 16 | $13,741 |
| XareltoRivaroxaban | 23 | $11,871 |
| TrintellixVortioxetine Hydrobromide | 23 | $10,936 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $10,765 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,872 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $8,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Stiolto Respimat | $1,569 | $192,536227 claims |
| Novo NordiskOzempic | $818 | $141,701129 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $570 | $48,67379 claims |
| MerckJanuvia, Janumet | $155 | $48,66859 claims |
| PfizerEliquis | $672 | $40,30457 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $748 | $22,16429 claims |
| Lilly USA, LLCMounjaro | $468 | $15,28914 claims |
| Johnson & JohnsonXarelto | $320 | $11,87123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $159 | $10,93623 claims |
| NovartisEntresto | $172 | $8,36912 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $4,514428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Amarillo
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.